Abstract:Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is an untreatable autosomal dominant neurodegenerative disease, and the most common such inherited ataxia worldwide. The mutation in SCA3 is the expansion of a polymorphic CAG tri-nucleotide repeat sequence in the C-terminal coding region of the ATXN3 gene at chromosomal locus 14q32.1. The mutant ATXN3 protein encoding expanded glutamine (polyQ) sequences interacts with multiple proteins in vivo, and is deposited as aggregates in the SCA3 brain. A large body of literature suggests that the loss of function of the native ATNX3-interacting proteins that are deposited in the polyQ aggregates contributes to cellular toxicity, systemic neurodegeneration and the pathogenic mechanism in SCA3. Nonetheless, a significant understanding of the disease etiology of SCA3, the molecular mechanism by which the polyQ expansions in the mutant ATXN3 induce neurodegeneration in SCA3 has remained elusive. In the present study, we show that the essential DNA strand break repair enzyme PNKP (polynucleotide kinase 3'-phosphatase) interacts with, and is inactivated by, the mutant ATXN3, resulting in inefficient DNA repair, persistent accumulation of DNA damage/strand breaks, and subsequent chronic activation of the DNA damage-response ataxia telangiectasia-mutated (ATM) signaling pathway in SCA3. We report that persistent accumulation of DNA damage/strand breaks and chronic activation of the serine/threonine kinase ATM and the downstream p53 and protein kinase C-δ pro-apoptotic pathways trigger neuronal dysfunction and eventually neuronal death in SCA3. Either PNKP overexpression or pharmacological inhibition of ATM dramatically blocked mutant ATXN3-mediated cell death. Discovery of the mechanism by which mutant ATXN3 induces DNA damage and amplifies the pro-death signaling pathways provides a molecular basis for neurodegeneration due to PNKP inactivation in SCA3, and for the first time offers a possible approach to treatment.

The Machado-Joseph Disease Deubiquitinase Ataxin-3 Regulates the Stability and Apoptotic Function of P53.

Research on Screening and Identification of Proteins Interacting with Ataxin-3.

ATAD3B is a Mitophagy Receptor Mediating Clearance of Oxidative Stress‐induced Damaged Mitochondrial DNA

Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3

The deubiquitinase function of ataxin-3 and its role in the pathogenesis of Machado-Joseph disease and other diseases

Determining The Fate Of Neurons In Sca3: Atx3, A Rising Decision Maker In Response To Dna Stresses And Beyond

Ataxin-3 Regulates Aggresome Formation of Copper-Zinc Superoxide Dismutase (SOD1) by Editing K63-linked Polyubiquitin Chains*

Absence of ataxin-3 leads to cytoskeletal disorganization and increased cell death

Ataxin-3 Protects Cells Against H2O2-induced Oxidative Stress by Enhancing the Interaction Between Bcl-XL and Bax

ATXN3: a multifunctional protein involved in the polyglutamine disease spinocerebellar ataxia type 3

Ubiquitin-interacting motifs of ataxin-3 regulate its polyglutamine toxicity through Hsc70-4-dependent aggregation

p53 mediates mitochondria dysfunction-triggered autophagy activation and cell death in rat striatum.

Sumo-1 Modification On K166 Of Polyq-Expanded Ataxin-3 Strengthens Its Stability And Increases Its Cytotoxicity

The BAG2 and BAG5 Proteins Inhibit the Ubiquitination of Pathogenic Ataxin3-80Q.

Ataxin-3 Promotes Genome Integrity by Stabilizing Chk1.

Phosphorylation of Ataxin-3 by Glycogen Synthase Kinase 3β at Serine 256 Regulates the Aggregation of Ataxin-3

The role of the mammalian DNA end-processing enzyme polynucleotide kinase 3'-phosphatase in spinocerebellar ataxia type 3 pathogenesis

PIAS1 S510G variant acts as a genetic modifier of spinocerebellar ataxia type 3 by selectively impairing mutant ataxin-3 proteostasis

Phosphorylation of ataxin-3 by glycogen synthase kinase 3beta at serine 256 regulates the aggregation of ataxin-3

Spinocerebellar Ataxia Type 3 Pathophysiology—Implications for Translational Research and Clinical Studies

p45, an ATPase subunit of the 19S proteasome, targets the polyglutamine disease protein ataxin-3 to the proteasome.